Claro Advisors LLC Sells 434 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Claro Advisors LLC reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.2% during the 3rd quarter, HoldingsChannel reports. The fund owned 9,780 shares of the company’s stock after selling 434 shares during the period. IDEXX Laboratories accounts for about 0.6% of Claro Advisors LLC’s holdings, making the stock its 28th largest position. Claro Advisors LLC’s holdings in IDEXX Laboratories were worth $4,941,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. International Assets Investment Management LLC boosted its holdings in shares of IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after purchasing an additional 527,460 shares during the period. Clearbridge Investments LLC lifted its position in IDEXX Laboratories by 696.0% in the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company’s stock worth $171,891,000 after buying an additional 308,493 shares during the last quarter. Vontobel Holding Ltd. boosted its stake in IDEXX Laboratories by 3,325.0% during the third quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock worth $111,229,000 after buying an additional 213,731 shares during the period. American Century Companies Inc. increased its position in IDEXX Laboratories by 46.0% during the second quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock valued at $274,179,000 after acquiring an additional 177,226 shares during the last quarter. Finally, 1832 Asset Management L.P. increased its position in IDEXX Laboratories by 4,193.1% during the second quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company’s stock valued at $62,601,000 after acquiring an additional 125,498 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on IDXX shares. BTIG Research assumed coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They set a “buy” rating and a $580.00 price target for the company. Piper Sandler reissued a “neutral” rating and issued a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. JPMorgan Chase & Co. reduced their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, Barclays decreased their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $552.38.

IDEXX Laboratories Trading Down 0.6 %

Shares of NASDAQ:IDXX opened at $420.91 on Friday. The company has a market capitalization of $34.47 billion, a PE ratio of 40.59, a P/E/G ratio of 3.67 and a beta of 1.36. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 12-month low of $404.74 and a 12-month high of $583.39. The business’s fifty day simple moving average is $468.32 and its 200-day simple moving average is $482.73.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. During the same period last year, the business earned $2.53 EPS. The company’s revenue was up 6.6% compared to the same quarter last year. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.